Amgen reported Phase 3 results showing its Imdelltra (tarlatamab) in combination with AstraZeneca’s Imfinzi (durvalumab) reduced the risk of death by 58% versus Imfinzi alone in a first-line maintenance setting for certain small-cell lung cancer patients. The findings were presented ahead of full details, with Amgen highlighting a substantial separation on clinical outcomes. The update extends the competitive landscape for first-line immunotherapy-based strategies in SCLC, where durability and overall survival remain key decision points for clinicians and payers. While the report is focused on unadjusted endpoints, the magnitude of the relative reduction sets expectations for further scrutiny as full efficacy, subgroup, and safety detail emerge.